Tecemotide: An antigen-specific cancer immunotherapy

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3383-3393

  Wurz, Gregory T ^a   Kao, Chiao Jung ^a   Wolf, Michael ^b   DeGregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Merck Serono GmbH   (Germany)

Author keywords

Chemoradiotherapy; Immunotherapy; MUC1; Non small cell lung cancer; Tecemotide

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCYLVALYLTHREONYLSERYLALANYLPROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLYLGLYCYLSERYLTHREONYLALANINE; SERYLTHREONYLALANYLPROLYLPROLYLALANYLHISITDYLGLYCYLVALYLTHREONYLSERYLALANYLPROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLYLGLYCYLSERYLTHREONYLALANYLPROLYLPROLINE; TECEMOTIDE; THREONYLALANYLPROLYLPROLYLALANYLHISTIDYLGLYCYLVALYLTHREONYLSERYLALANYLPROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLYLGLYCYLSERYLTHREONYLALANYLPROLYLPROLINE; UNCLASSIFIED DRUG; CANCER VACCINE; L-BLP25; MEMBRANE PROTEIN; MUC1 PROTEIN, HUMAN; MUCIN 1; TUMOR ANTIGEN;

ADENOCARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; LIPOSOMAL DELIVERY; LUNG CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TRANSGENIC MOUSE; TREATMENT INDICATION; TREATMENT OUTCOME; ANIMAL; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOUSE; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MUCIN-1;

EID: 84921742575     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29836     Document Type: Review

References (79)

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
2. Szabo E. MUC1 expression in lung cancer. Methods Mol Med 2003; 74:251-8; PMID:12415700
3. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2004; 2:4; PMID:14711375; http://dx.doi.org/10.1186/1477-7827-2-4
4. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003; 26:47-62; PMID:12514429; http://dx.doi.org/10.1097/00002371-200301000-00006
5. Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol 1994; 14:293-309; PMID:7538768; http://dx.doi.org/10.1615/CritRevImmunol.v14.i3-4.40
6. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011; 50:261-8; PMID:21717081; http://dx.doi.org/10.1007/s12026-011-8214-1
7. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2012; 109:261-6; PMID:22171012; http://dx.doi.org/10.1073/pnas.1115166109
8. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82:249-93; PMID:14975259; http://dx.doi.org/10.1016/S0065-2776(04)82006-6
9. Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H, Beckhove P. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005; 105:2132-4; PMID:15561890; http://dx.doi.org/10.1182/blood-2004-01-0366
10. Gaidzik N, Kaiser A, Kowalczyk D, Westerlind U, Gerlitzki B, Sinn HP, Schmitt E, Kunz H. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domainsinduction of a strong immune response against breast tumor tissues. Angew Chem Int Ed Engl 2011; 50:9977-81; PMID:21910197; http://dx.doi.org/10.1002/anie.201104529
11. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994; 153:2102-9; PMID:8051415
12. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, et al. Tecemotide (L-BLP25) versus. placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15:59-68; PMID:24331154; http://dx.doi.org/10.1016/S1470-2045(13)70510-2
13. Hilkens J, Vos HL, Wesseling J, Boer M, Storm J, van der Valk S, Calafat J, Patriarca C. Is episialin/MUC1 involved in breast cancer progression? Cancer Lett 1995; 90:27-33; PMID:7720039; http://dx.doi.org/10.1016/0304-3835(94)03674-8
14. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263:12820-3; PMID:3417635
15. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003; 33:3242-54; PMID:14635032; http://dx.doi.org/10.1002/eji.200324189
16. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 1999; 194:143-9; PMID:10383817; http://dx.doi.org/10.1006/cimm.1999.1512
17. Purcell AW, van Driel IR, Gleeson PA. Impact of glycans on T-cell tolerance to glycosylated self-antigens. Immunol Cell Biol 2008; 86:574-9; PMID:18626489; http://dx.doi.org/10.1038/icb.2008.48
18. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43:1072-6; PMID:2471698; http://dx.doi.org/10.1002/ijc.2910430620
19. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC, Jr., Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51:2908-16; PMID:1709586
20. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 1998; 4:397-403; PMID:9791863; http://dx.doi.org/10.1016/S1357-4310(98)01322-7
21. Konowalchuk JD, Agrawal B. MUC1 mucin is expressed on human T-regulatory cells: function in both co-stimulation and co-inhibition. Cell Immunol 2012; 272:193-9; PMID:22078269; http://dx.doi.org/10.1016/j.cellimm.2011.10.012
22. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137:1337-42; PMID:21744082; http://dx.doi.org/10.1007/s00432-011-1003-3
23. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674-81; PMID:16170175; http://dx.doi.org/10.1200/JCO.2005.13.011
24. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001; 3:49-57; discussion 8; PMID:14656392; http://dx.doi.org/10.3816/CLC.2001.n.018
25. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011; 11:430; PMID:21982342; http://dx.doi.org/10.1186/1471-2407-11-430
26. Limacher JM, Quoix E. TG4010: A therapeutic vaccine against MUC1 expressing tumors. Oncoimmunology 2012; 1:791-2; PMID:22934285; http://dx.doi.org/10.4161/onci.19863
27. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12:1125-33; PMID:22019520; http://dx.doi.org/10.1016/S1470-2045(11)70259-5
28. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011; 60:261-71; PMID:21069322; http://dx.doi.org/10.1007/s00262-010-0935-9
29. Arlen PM, Pazdur M, Skarupa L, Rauckhorst M, Gulley JL. A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer 2006; 7:176-9; PMID:16800982; http://dx.doi.org/10.3816/CBC.2006.n.032
30. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17:7164-73; PMID:22068656; http://dx.doi.org/10.1158/1078-0432.CCR-11-0649
31. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; 258: 879-86; PMID:23657083; http://dx.doi.org/10.1097/SLA.0b013e318292919e
32. Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, Bell KE, McCall JL, Wolf M, DeGregorio M. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res 2012; 18:2861-71; PMID:22434666; http://dx.doi.org/10.1158/1078-0432.CCR-12-0168
33. Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM, Wolf M, DeGregorio MW. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res 2014; 2:581-9; PMID:24894093; http://dx.doi.org/10.1158/2326-6066.CIR-13-0205
34. Wurz GT, Gutierrez AM, Greenberg BE, Vang DP, Griffey SM, Kao CJ, Wolf M, Degregorio MW. Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. J Transl Med 2013; 11:64; PMID:23496860; http://dx.doi.org/10.1186/1479-5876-11-64
35. Kao CJ, Wurz GT, Schroder A, Wolf M, DeGregorio MW. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy. Oncoimmunology 2013; 2:e26285; PMID:24498545; http://dx.doi.org/10.4161/onci.26285
36. DeGregorio M, Soe L, Wolf M. Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis 2014; 6:571-3, Apr 25; PMID:24976972; http://dx.doi.org/10.3978/j.issn.2072-1439.2014.05.15
37. Ding L, Lalani EN, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PY, Taylor-Papadimitriou J, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993; 36:9-17; PMID:8422670; http://dx.doi.org/10.1007/BF01789125
38. Lalani EN, Berdichevsky F, Boshell M, Shearer M, Wilson D, Stauss H, Gendler SJ, Taylor-Papadimitriou J. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J Biol Chem 1991; 266:15420-6; PMID:1714457
39. Barbon CM, Yang M, Wands GD, Ramesh R, Slusher BS, Hedley ML, Luby TM. Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization. Cell Immunol 2010; 262:150-61; PMID:20206921; http://dx.doi.org/10.1016/j.cellimm.2010.02.007
40. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8 +subset. Cancer Res 1987; 47:3317-21; PMID:2953413
41. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201:1591-602; PMID:15883172; http://dx.doi.org/10.1084/jem.20042167
42. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25 +T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-8; PMID:15591121; http://dx.doi.org/10.1182/blood-2004-06-2410
43. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006; 16:141-6; PMID:16786137
44. Fung PY, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990; 50:4308-14; PMID:2364387
45. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19:309-16; PMID:8877724; http://dx.doi.org/10.1097/00002371-199607000-00006
46. Samuel J, Budzynski WA, Reddish MA, Ding L, Zimmermann GL, Krantz MJ, Koganty RR, Longenecker BM. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 1998; 75:295-302; PMID:9462722; http://dx.doi.org/10.1002/(SICI)1097-0215(19980119)75:2%3c295::AID-IJC20%3e3.0.CO;2-B
47. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast cancer? Cancer Res 1995; 55:2257-61; PMID:7538899
48. Agrawal B, Reddish MA, Longenecker BM. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 1996; 157:2089-95; PMID:8757331
49. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995; 155:4766-74; PMID:7594478
50. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998; 10:1907-16; PMID:9885912; http://dx.doi.org/10.1093/intimm/10.12.1907
51. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, Longenecker BM, Samuel J. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998; 9:451-8; PMID:9667946; http://dx.doi.org/10.1021/bc970183n
52. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998; 58:315-21; PMID:9443411
53. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12:954-61; PMID:1312220
54. Oh SA, Li MO. TGF-beta: guardian of T cell function. J Immunol 2013; 191:3973-9; PMID:24098055; http://dx.doi.org/10.4049/jimmunol.1301843
55. Babina M, Kirn F, Hoser D, Ernst D, Rohde W, Zuberbier T, Worm M. Tamoxifen counteracts the allergic immune response and improves allergeninduced dermatitis in mice. Clin Exp Allergy 2010; 40:1256-65; PMID:20337649; http://dx.doi.org/10.1111/j.1365-2222.2010.03472.x
56. Behjati S, Frank MH. The effects of tamoxifen on immunity. Curr Med Chem 2009; 16:3076-80; PMID:19689284; http://dx.doi.org/10.2174/092986709788803042
57. Chen H, Tritton TR, Kenny N, Absher M, Chiu JF. Tamoxifen induces TGF- b 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 1996; 61:9-17; PMID:8726350; http://dx.doi.org/10.1002/(SICI)1097-4644(19960401)61:1%3c9::AID-JCB2%3e3.0.CO;2-Z
58. Joffroy CM, Buck MB, Stope MB, Popp SL, Pfizenmaier K, Knabbe C. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res 2010; 70:1314-22; PMID:20145137; http://dx.doi.org/10.1158/0008-5472.CAN-09-3292
59. Komi J, Lassila O. Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells. Blood 2000; 95:2875-82; PMID:10779434
60. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-41; PMID:12974478; http://dx.doi.org/10.1038/nri1150
61. Srinivasan R, Van Epps DE. Specific active immunotherapy of cancer: potential and perspectives. Rev Recent Clin Trials 2006; 1:283-92; PMID:18473980; http://dx.doi.org/10.2174/157488706778250113
62. Tabi Z, Man S. Challenges for cancer vaccine development. Adv Drug Deliv Rev 2006; 58:902-15; PMID:16979786; http://dx.doi.org/10.1016/j.addr.2006.05.004
63. Vang DP, Wurz GT, Griffey SM, Kao CJ, Gutierrez AM, Hanson GK, Wolf M, DeGregorio MW. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development. J Vis Exp 2013; e50868; PMID:24300078; http://dx.doi.org/10.3791/50868
64. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 2004; 122:61-9; PMID:15272531; http://dx.doi.org/10.1309/9R6673QEC06D86Y4
65. Scholfield DP, Simms MS, Bishop MC. MUC1 mucin in urological malignancy. BJU Int 2003; 91:560-6; PMID:12656915; http://dx.doi.org/10.1046/j.1464-410X.2003.04132.x
66. Walsh MD, Hohn BG, Thong W, Devine PL, Gardiner RA, Samaratunga ML, McGuckin MA. Mucin expression by transitional cell carcinomas of the bladder. Br J Urol 1994; 73:256-62; PMID:8162502; http://dx.doi.org/10.1111/j.1464-410X.1994.tb07514.x
67. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998; 47:1-12; PMID:9755873; http://dx.doi.org/10.1007/s002620050498
68. Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998; 76:817-23; PMID:9626347; http://dx.doi.org/10.1002/(SICI)1097-0215(19980610)76:6%3c817::AID-IJC9%3e3.0.CO;2-0
69. Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, Nishio M, Senger S, Morsli N, Tamura T. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. Jpn J Clin Oncol 2011; 41:718-22; PMID:21393255; http://dx.doi.org/10.1093/jjco/hyr021
70. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 2005; 4:249-57; PMID:16026241; http://dx.doi.org/10.1586/14760584.4.3.249
71. Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulieres D. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2010; 11:391-5; PMID:21071331; http://dx.doi.org/10.3816/CLC.2010.n.101
72. North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 2006; 176:91-5; PMID:16753376; http://dx.doi.org/10.1016/S0022-5347(06)00494-0
73. Ramalingam S, Mitchell P, Vansteenkiste J, Debus J, Curran W, Socinski MA, Helwig C, Falk M, Butts C. START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy. Abstract TPS7608. 50th Annual Meeting of the American Society of Clinical Oncology May 30-June 3, 2014. Chicago, Illinois: Am Soc Clin Oncol 2014
74. Schimanski CC, Mohler M, Schon M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vohringer M, Heike M, et al. LICC: LBLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, doubleblinded phase II trial. BMC Cancer 2012; 12:144; PMID:22494623; http://dx.doi.org/10.1186/1471-2407-12-144
75. Kasper S, Moehler M, Hegewisch-Becker S, Overkamp F, Bechstein WO, Kullmann F, Lang H, Schoen M, Smith-Machnow V, Seehofer D, et al. A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. J Clin Oncol 2014; 32(15S):TPS3658 (abstract).
76. National Institutes of Health. Tecemotide (L-BLP25) in Rectal Cancer (SPRINT) NCT01507103. http://www.clinicaltrials.gov/ct2/show/NCT01507103?term=NCT01507103&rank=1. Accessed May 30, 2014
77. International Clinical Trials Registry Platform. An open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancer. http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2011-004822-85-AT. Accessed May 30, 2014
78. National Institutes of Health. L-BLP25 (Stimuvax) in Prostate Cancer NCT01496131. http://www. clinicaltrials.gov/ct2/show/NCT01496131?term=NCT01496131&rank=1. Accessed May 30, 2014
79. National Institutes of Health. BLP25 Liposome Vaccine and Bevacizumab after Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer that cannot be Removed by Surgery NCT00828009. http://www.clinicaltrials.gov/ct2/show/NCT00828009?term=NCT00828009&rank=1. Accessed May 30, 2014